Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Brendan Joseph Kelly · UNIVERSITY OF PENNSYLVANIA · 2023 · $208,815 — SUMMARY – CORE C (CLINICAL CORE) Core C (Clinical Core) will support the overall mVACS program goal to develop modified mRNA vaccines to eliminate C.difficile infection (CDI) by developing an infrastructure for CDI human subject identification, specimen biobanking, and metadata collection to study t…
Benjamin L Miller · UNIVERSITY OF ROCHESTER · 2023 · $387,521 — Abstract The field of Osteoimmunology was established in 2005 to understand how bone influences immune and hematopoietic cells, as well as how hematopoietic and immune cells influence bone, in clinical conditions like osteomyelitis. However, several critical research tools and rigorously validated p…
Scott Dexter Boyd · STANFORD UNIVERSITY · 2023 · $541,840 — ABSTRACT – Project 3 The focus of Project 3 is to study antigen-specific B cell and plasma cell responses in the context of two timely and fundamental topics in vaccinology: (i) Immunology of COVID-19 vaccines, and (ii) the impact of the microbiota on immune responses to vaccination. The COVID-19 pa…
DREW WEISSMAN · UNIVERSITY OF PENNSYLVANIA · 2023 · $87,740 — SUMMARY – CORE A (Administration Core) The "mRNA Vaccines for C. difficile Suppression” program (mVACS) consists of a highly interactive team of investigators who are seeking to develop an mRNA vaccine platform to provide protection against Clostridioides difficile-associated infection and disease. …
Roger Keith Reeves · HARVARD UNIVERSITY · 2023 · $317,952 — PROJECT SUMMARY/ABSTRACT Advanced Lab Technologies Core (Core I) One of the greatest added values of the Harvard University (HU) CFAR has been accelerated member access to new and emerging technologies. Science is accelerated by changes in technology, and the evolution of flow cytometric, imaging an…
Karen S. Anderson · YALE UNIVERSITY · 2023 · $437,838 — SUMMARY Human papillomavirus (HPV)-associated neck squamous cell carcinoma (HNSCC) represents an increasing proportion of HNSCC. The incidence of HPV+ HNSCC has dramatically increased over the last 2 decades and in 2012 surpassed uterine cervical cancer as the most common HPV-related malignancy in t…
Patrick Kellish · UNIVERSITY OF FLORIDA · 2023 · $78,287 — FLOW CYTOMETRY AND CONFOCAL MICROSCOPY SHARED RESOURCE (CYT-SR): ABSTRACT CYT-SR provides University of Florida Health Cancer Center (UFHCC) members with cost-effective, state-of- the-art flow cytometry and modern confocal microscopy expertise, instrumentation, and services to support their research…
Christian Jobin · UNIVERSITY OF FLORIDA · 2023 · $77,848 — CANCER THERAPEUTICS AND HOST RESPONSE (CTHR) PROGRAM: ABSTRACT The University of Florida Health Cancer Center (UFHCC) CTHR program integrates investigators with expertise in microbiome, immunology, cancer biology, bioengineering, medicinal chemistry, and clinical trial development to advance cancer …
BRUXANNE EL-KAMMASH · UNIVERSITY OF CHICAGO · 2023 · $1,964,933 — Vaccines are formulated with adjuvants to stimulate the immune system so that the vaccine can be more effective at preventing disease. Our goal is to create an adjuvant formulation that overcomes a limitation in many adjuvants - customization of the immune response for a desired immunological outco…
Dan H. Barouch · FRED HUTCHINSON CANCER CENTER · 2022 · $55,953,346 — FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the …
Duane R. Wesemann · BRIGHAM AND WOMEN'S HOSPITAL · 2022 · $686,383 — Project Summary Antibodies specific for pathogenic threats can provide immediate protection from infectious disease but longevity of an antibody responses after vaccination or infection can be highly variable. Responses induced by some live vaccines can persist for a lifetime, whereas protein-based …
Valerian Nakaar · CAROGEN CORPORATION · 2022 · $263,991 — PROJECT ABSTRACT Current vaccines are mainly strain-specific and have limited efficacy in preventing new, potentially pandemic influenza strains. Interest in a universal influenza vaccine (UIV) to prevent future pandemics has been greatly boosted by the success of mRNA-based coronavirus vaccines. Ho…
Peter R Hoffmann · UNIVERSITY OF HAWAII AT MANOA · 2022 · $45,829 — Selenium (Se) is an essential micronutrient important for many aspects of human health, including optimal immune responses. The biological effects of Se are exerted mainly through its incorporation into selenoproteins as the amino acid, selenocysteine (Sec). Twenty-five selenoproteins have been iden…
DAVID WANG · WASHINGTON UNIVERSITY · 2022 · $247,061 — PROJECT SUMMARY The incidence of tick-borne diseases has increased significantly over the past 25 years due to climate change, shifting population demographics of both humans and ticks, and inadequate vector control. Including economic and societal costs, it is estimated that tick-borne diseases cos…
Scott F Michael · COLLEGE AT OSWEGO · 2022 · $155,018 — PROJECT SUMMERY Most currently available vaccines, especially live and mRNA-based COVID-19 vaccines, are temperature sensi- tive and require stringent cold-chain maintenance, entailing their storage and distribution at recommended tem- peratures from production to administration. This necessity impo…
Biana Godin · METHODIST HOSPITAL RESEARCH INSTITUTE · 2022 · $444,125 — ABSTRACT It is estimated that annually ~3 million Traumatic brain injury (TBI) cases occur in the U.S. Moderate to severe TBI can cause significant impairments in mental and motor functions or death. There are no effective therapies to improve cognitive abilities after moderate-severe TBI. Many nove…
Tzu-yin Lin · THERANOSTEC, INC. · 2022 · $399,999 — Title: Sub-100 nm and scalable self-therapeutic nanoparticles to target autophagy in pancreatic cancer Project Summary The 5-year survival rate of pancreatic ductal adenocarcinoma (PDAC) is less than 10% and the lack of effective treatment is one of the major impediments for the clinical management …
Kristin Palmsten · HEALTHPARTNERS INSTITUTE · 2022 · $618,968 — The efficacy of coronavirus disease (COVID-19) vaccines available in the US is up to 95% against symptomatic COVID-19. However, pregnant and lactating individuals were excluded from initial clinical trials. COVID-19 vaccine trials are now underway in pregnant women in their second or third trimester…
KENT E. KESTER · INTERNATIONAL AIDS VACCINE INITIATIVE · 2022 · $465,219 — Project Summary/Abstract Tuberculosis remains one of the top ten leading causes of death worldwide (1). Based on the most current information from WHO 2020 report, in 2019 an estimated 1.4 million people died from TB and approximately 10,000,000 fell ill (2). The COVID-19 pandemic has led to massive…
CHRISTINA CHAMBERS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2022 · $3,069,641 — Project Summary/Abstract Pregnant people are particularly vulnerable to SARS-CoV-2 and at risk of developing a more serious or complicated disease course, including about a 70% increased risk of death. Infection in pregnancy also appears to be related to increased risk for preterm delivery as well a…